Cite
HARVARD Citation
Shebl, A. et al. (n.d.). 17. Benefit-Risk Profile of Intravenous Immunoglobulin (IVIG) and Subcutaneous Immunoglobulin (SCIG) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): The PATH study. Clinical neurophysiology. 131 (3), pp. e7-e8. [Online].